Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer

Aim: In the single-arm MOUNTAINEER trial (NCT03043313) tucatinib in combination with trastuzumab showed an objective response rate (ORR) of 39.3% in patients with previously treated, HER2+unresectable or metastatic colorectal cancer (mCRC). This study compared the efficacy of tucatinib in combinat...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Claire Watkins, Cyndy Simon, Peter Martin, Regina Leadley, Gabrielle Redhead, Edward Neuberger, Karen Bartley
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Becaris Publishing Limited 2026-01-01
Serie:	Journal of Comparative Effectiveness Research
Soggetti:	colorectal cancer comparative effectiveness matching-adjusted indirect comparison survival
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!